Hemolytic Uremic Syndrome: Another FAT RN?
Hemolytic uremic syndrome (HUS) is a member of a larger group called thrombotic-microangiopathies (TMA). HUS leads to endothelial injury, platelet activation, and vaso-occlusive fibrin and platelet thrombi accumulation that lead to destruction of red blood cells and injury to the brain, heart, lungs, GI tract, and kidneys. HUS can result from shiga toxin exposure or from a defect in complement activity.
KeywordsHemolytic uremic syndrome Shiga toxin Atypical hemolytic uremic syndrome E. coli 0157:H7 Plasmapheresis Autoimmune Complement system
Klein—Nothing to disclose
Kaide—Callibra, Inc.-Discharge 123 medical software company. Medical Advisory Board Portola Pharmaceuticals. I have no relationship with a commercial company that has a direct financial interest in subject matter or materials discussed in article or with a company making a competing product.
- 6.Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TG, Dong J, Moake JL. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von willebrand factor multimers. Blood. 2005;106:4199–209. https://doi.org/10.1182/blood-2005-05-2111.CrossRefPubMedPubMedCentralGoogle Scholar